Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

Area of Science:

• Immunotherapy
• Gene Therapy
• Oncology

Background:

• Interleukin-12 (IL-12) gene therapy via dendritic cells (DCs) promotes tumor regression.
• The temporal requirements for IL-12 production by DCs in therapy remain unclear.

Purpose of the Study:

• To investigate the temporal requirements of IL-12p70 production by gene-engineered DCs for therapeutic efficacy.
• To assess the safety and efficacy of a conditional IL-12 gene therapy system.

Main Methods:

• Developed a conditional expression system (rAd.RheoIL12) for tightly regulated IL-12p70 production in DCs.
• Administered rAd.RheoIL12-infected DCs (DC.RheoIL12) intratumorally in a murine B16 melanoma model.
• Evaluated therapeutic outcomes based on ligand administration timing and duration, and assessed immune responses.

Main Results:

• DC.RheoIL12 therapy induced B16 tumor regression when ligand administration occurred within 24 hours and was sustained for ~5 days.
• Treatment efficacy correlated with systemic anti-B16 CD8(+) T cell cross-priming.
• Enhanced survival of adoptively transferred DC.RheoIL12 in tumors and lymph nodes was observed.

Conclusions:

• Sustained, controlled IL-12p70 production by DCs is crucial for effective anti-tumor immunotherapy.
• This conditional gene therapy approach offers a tunable method for IL-12 delivery, enhancing safety and efficacy.
• The system demonstrated potential for ameliorating toxicity in combination therapies.